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Abstract
Chemopreventive effects and associated mechanisms of grape seed extract (GSE) against intestinal/colon cancer de-
velopment are largely unknown. Herein, we investigated GSE efficacy against intestinal tumorigenesis in APCmin/+
mice. Female APCmin/+ mice were fed control or 0.5% GSE (wt/wt) mixed AIN-76A diet for 6 weeks. At the end of
the experiment, GSE feeding decreased the total number of intestinal polyps by 40%. The decrease in polyp forma-
tion in the small intestine was 42%, which was mostly in its middle (51%) and distal (49%) portions compared with
the proximal one. GSE also decreased polyp growth where the number of polyps of 1 to 2 mm in size decreased by
42% and greater than 2 mm in size by 71%, without any significant change in polyps less than 1 mm in size. Immuno-
histochemical analyses of small intestinal tissue samples revealed a decrease (80%-86%) in cell proliferation and an in-
crease (four- to eight-fold) in apoptosis. GSE feeding also showed decreased protein levels of cyclooxygenase-2 (COX-2)
(56%-64%), inducible nitric oxide synthase (iNOS) (58%-60%), and β-catenin (43%-59%) but an increased Cip1/p21–
positive cells (1.9- to 2.6-fold). GSE also decreased cyclin D1 and c-Myc protein levels in small intestine. Together, these
findings show the chemopreventive potential of GSE against intestinal polyp formation and growth in APCmin/+ mice,
which was accompanied with reduced cell proliferation and increased apoptosis together with down-regulation in
COX-2, iNOS, β-catenin, cyclin D1, and c-Myc expression, but increased Cip1/p21. In conclusion, the present study sug-
gests potential usefulness of GSE for the chemoprevention of human intestinal/colorectal cancer.
Neoplasia (2010) 12, 95–102
Introduction
Colorectal cancer (CRC), which often results from a combination of
genetic predisposition and environmental factors, is a major cause of
cancer-related deaths among both men and women in the United
States [1]. Substantial evidence from epidemiological and experimen-
tal studies indicate that a Western-style diet, high in fat and red meat
as well as diet low in fibers and vegetables, increases the risk of CRC
[2,3]. Hence, identification of dietary constituents that prevent CRC
is important and a major focus of research in recent years. Recently,
there has been a keen interest in the protective and therapeutic effects
of certain plant chemicals on chronic diseases including cancer. Es-
pecially, dietary phytochemicals that consist of a wide variety of bio-
logically active compounds have drawn a great deal of attention from
both the scientific community and the general public owing to their
demonstrated ability to suppress cancers [4].
One such most notable agent is grape seed extract (GSE), which has
shown promising chemopreventive and anticancer effects in various
in vitro and in vivo models [5–8]. GSE is a complex mixture of various
polyphenols that are generally referred to as proanthocyanidins and has
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long been marketed in the United States as a dietary supplement owing
to multiple health benefits [9,10]. Grape seed proanthocyanidins have
been demonstrated to exert a novel spectrum of biological, pharmaco-
logical, therapeutic, and chemoprotective properties against oxygen free
radicals and oxidative stress [11,12]. In several continuing studies by us
and others, GSE has been shown to reduce the incidence of carcinogen-
inducedmammary tumors in rats and skin tumors inmice and to inhibit
the growth of different human cancer cells in vitro and in vivo [13–16].
A recent study from our laboratory has also demonstrated the inhibitory
effect of GSE on prostate cancer growth and progression in the trans-
genic adenocarcinoma of themouse prostate (TRAMP)model [17]. The
aim of the present study was to investigate whether GSE exerts chemo-
preventive efficacy against the intestinal tumorigenesis in APCmin/+
mouse model.
APCmin/+ mice are considered as a genetically relevant animal model
mimicking human intestinal carcinogenesis [18]. These mice carry a
germ line nonsense mutation at codon 850 of the mouse homolog of
the human adenomatous polyposis coli (APC ) gene and spontaneously
develop multiple polyps in the small and large intestines at the age of
10 to 12 weeks [19]. The APC gene is a tumor-suppressor gene, and its
mutation has been directly implicated in the development of both
human familial adenomatous polyposis (FAP) and sporadic CRC
[20]. Hence, APCmin/+ mice are considered an ideal experimental
model for analysis and prevention of human CRC. Therefore, in this
study, we used the APCmin/+ mice model to investigate the inhibitory
activity of GSE against intestinal tumorigenesis and the possible mecha-
nisms involved in the inhibitory action.
Materials and Methods
Animals and Treatment Protocol
Six-week-old female APCmin/+ mice were purchased from the Jackson
laboratories (Bar Harbor, ME) and maintained in the animal house fa-
cility at the University of ColoradoDenver. Animals weremaintained in
12-hour light/dark cycles with free access to water and food (AIN-76A
powder diet from Dyets Inc., Bethlehem, PA). After 1 week of acclima-
tization, animals were randomly divided into two groups of eight ani-
mals each and fed AIN-76A control diet or 0.5%GSE (wt/wt) mixed in
AIN-76Apowder diet using a powder diet feeder, ad libitum for 6 weeks.
GSE-standardized preparation, constituting of 89.3% (wt/wt) procya-
nidins, 6.6% of monomeric flavonols, 2.24% of moisture content,
1.06% of protein, and 0.8% of ash, was a kind gift from its commercial
vendor Kikkoman Corp (Noda City, Japan). The animals were weighed
weekly once and monitored regularly for any signs of weight loss. At
13 weeks of age, the animals were killed by CO2 followed by cervical
dislocation; the intestine was spread onto filter paper, opened longitudi-
nally with fine scissors, and cleaned with sterile ice-cold PBS using a soft
brush. The small intestine was divided into three equal parts, namely
proximal, middle, and distal, and the large intestine consisted of cecum
and colon. All intestinal polyps were counted under a dissecting micro-
scope, and their sizes were measured with a digital caliper.
Immunostaining for Proliferating Cell Nuclear Antigen,
Cyclooxygenase-2, Nitric Oxide Synthase, β-Catenin,
Cip1/p21, Cyclin D1, and c-Myc
Intestinal tissues were fixed in 10% phosphate-buffered formalin for
10 hours at 4°C, dehydrated in ascending concentrations of ethanol,
cleared with xylene, and embedded in PolyFin (Triangle Biomedical
Sciences, Durham, NC). Paraffin-embedded tissue blocks were cut
with a rotary microtome into 4-μm sections and processed for immuno-
histochemical staining. Briefly, sections after deparaffinization and re-
hydration were treated with 0.01 M sodium citrate buffer (pH 6.0)
in a microwave for 30 minutes at full power for antigen-retrieval. Sec-
tions were then quenched of endogenous peroxidase activity by immers-
ing in 3% hydrogen peroxide for 5 minutes at room temperature.
The sections were either incubated with mouse monoclonal anti-
proliferating cell nuclear antigen (PCNA) antibody (1:400 dilutions;
Dako, Carpinteria, CA), rabbit polyclonal anti–cyclooxygenase-2
(COX-2) antibody (1:100 dilutions; Cell Signaling Technologies, San
Diego, CA), rabbit polyclonal anti-nitric oxide synthase (iNOS) anti-
body (1:200 dilutions; Abcam, Inc, Cambridge, MA), rabbit polyclonal
anti–β-catenin (1:100 dilutions; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), rabbit polyclonal anti–Cip1/p21 antibody (1:100 dilutions;
Lab Vision Corporation, Fremont, CA), cyclin D1 (1:200 dilutions;
Neomarkers, CA), or c-Myc (1:100 dilutions; Santa Cruz Biotechnology)
in PBS for 2 hours at room temperature in a humidity-controlled cham-
ber followed by overnight incubation at 4°C. In all the immuno-
histochemical staining, to rule out the nonspecific staining allowing
better interpretation of specific staining at the antigenic site, nega-
tively staining controls were used in which sections were incubated with
N-Universal Negative Control mouse or rabbit antibody (Dako) under
identical conditions. The sections were then incubated with appropriate
biotinylated secondary antibody for 1 hour at room temperature followed
by a 30-minute incubation with HRP-conjugated streptavidin. Color
development was performed by incubating with 3,3′-diaminobenzidine
for 10 minutes at room temperature. The sections were counterstained
with Harris hematoxylin, dehydrated, and mounted. The prolifera-
tion index was determined as the number of PCNA-positive cells ×
100 / total number of cells. Levels of immunostaining of COX-2, iNOS,
β-catenin, and c-Myc were quantified as 0, 1+, 2+, 3+, and 4+ represent-
ing nil, weak, moderate, strong, and very strong staining, respectively.
Cip1/p21 and cyclin D1 were quantified by counting positively stained
cells and total number of cells at 10 randomly selected fields from each
section at 400× magnifications, and data were presented as percent
positive cells.
Terminal Deoxynucleotidyl Transferase dUTP Nick End
Labeling Staining for Apoptotic Cells
Apoptotic cells were detected using the DeadEnd Colorimetric ter-
minal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
system (Promega, Madison, WI) following the manufacturer’s protocol
with some modifications. In brief, intestinal tissue sections after de-
paraffinization and rehydration were permeabilized with proteinase K
(30 mg/ml) for 1 hour at 37°C. Thereafter, the sections were quenched
of endogenous peroxidase activity using 3% hydrogen peroxide for
10 minutes. After thorough washing with 1× PBS, sections were incu-
bated with equilibration buffer for 10 minutes, and then the terminal
deoxynucleotidyl transferase reaction mixture was added to the sections,
except for the negative control, and incubated at 37°C for 1 hour. The
reaction was stopped by immersing the sections in 2× saline–sodium cit-
rate buffer for 15 minutes. Sections were then added with streptavidin-
HRP (1:500) for 30 minutes at room temperature, and after repeated
washings, sections were incubated with substrate 3,3′-diaminobenzidine
until color development (∼10 minutes). Sections were then mounted
after dehydration and observed under 400× magnifications for TUNEL-
positive cells. The apoptotic index was calculated as number of apoptotic
cells × 100 / total number of cells.
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Immunohistochemical and Statistical Analyses
All the microscopic immunohistochemical analyses were done using
Zeiss Axioscop 2 microscope (Carl Zeiss, Jena, Germany). Pictures were
taken by Kodak DC290 camera under 400× magnifications and pro-
cessed by Kodak Microscopy Documentation System 290 (Eastman
Kodak Company, Rochester, NY). The mean ± SE values were
obtained from the evaluation of multiple fields in each group. For each
animal, 10 representative fields were counted at 400× magnifications,
and the data represent the results from eight mice in each group. For the
statistical significance of the difference, the data were analyzed using
the SigmaStat 2.03 software (SPSS, Inc., Chicago, IL). The statistical
significance of difference between control and GSE-treated group was
determined by one-way analysis of variance followed by Student’s t test.
P < .05 was considered statistically significant.
Results
Dietary GSE Inhibits Multiplicity and Burden of Intestinal
Polyps without Any Toxicity in APCmin/+ Mice
All mice were monitored on a regular basis to investigate if dietary
GSE had any effect on body weight gain. Gain in body weights did
not differ significantly among the control and GSE-fed groups until
the end of the study (Figure 1A). Further, no considerable change in
food consumption (g/day per mouse) or histopathologic alterations
were found in any organs, including the liver, in mice due to GSE
supplementation in diet (data not shown). APCmin/+ mice in the
control group observed at 13 weeks of age developed an average of
43 intestinal tumors (polyps) per mouse, and most of these tumors
were populated in the small intestine. Dietary feeding of 0.5% GSE
for 6 weeks significantly reduced the number of total intestinal polyps
by 40% (from 43 per mouse in control to 26 per mouse in GSE-fed
group; P = .014). The prominent effect of GSE on the decrease in polyp
formation was observed in small intestine (42% decrease, P = .011;
Figure 1B). In particular, middle and distal portions of small intestine
showed a 51% (P = .009) and 49% (P = .018) decrease in the number
of polyps by GSE, respectively (Figure 1C). In size distribution analy-
sis, GSE strongly decreased the number of large size polyps (≥2 mm in
size by 71% [P < .001] and 1-2 mm in size by 42% [P = .03]), without
any significant change in polyps of less than 1 mm in size (Figure 1D).
These results indicate the inhibitory effect of GSE on polyp multiplic-
ity and growth without any toxicity in APCmin/+ mice.
Effects of Dietary GSE on Intestinal PCNA Labeling Index
and TUNEL-Positive Cells
To evaluate mechanisms involved in the chemopreventive ability of
GSE, we initially assessed its effect on cell proliferation and apoptosis.
The PCNA immunostaining and in situ apoptosis detection assays were
performed in different portions (proximal, middle, and distal) of the
small intestinal tissues from control and GSE-treated groups of mice.
PCNA is an auxiliary protein of DNA polymerase-δ and its level of
Figure 1. Effect of dietary feeding of GSE on intestinal tumorigenesis in APCmin/+ mice. Dietary feeding of GSE in AIN-76A diet (A) does
not affect body weight gain in APCmin/+ mice and (B) inhibits intestinal polyp formation (C) with the most prominent effect in middle and
distal regions of small intestine. (D) GSE also decreases the number of larger polyps (>1 mm) indicating its growth-inhibitory effect on
polyps in APCmin/+ mice.
Neoplasia Vol. 12, No. 1, 2010 Inhibition of Intestinal Tumorigenesis by GSE Velmurugan et al. 97
expression correlates cell with proliferation, and therefore, it is used as a
marker of cell proliferation [26]. The quantification of PCNA
immunohistochemical staining revealed that inhibition of polyp growth
by GSE was associated with a strong decrease (80%-86%, P < .01 to
P < .001) in cell proliferation in intestinal tissue (Figure 2A). In con-
trast, the apoptotic cells, as determined by TUNEL-positive cells, were
significantly increased (four- to eight-fold, P < .05) in mice treated with
0.5% GSE compared with the control mice (Figure 2B). Overall, these
results indicated the antiproliferative and proapoptotic effects of GSE in
intestinal tissue, which may, in part, account for its inhibitory effects on
polyp multiplicity and growth.
Effect of Dietary GSE on Intestinal COX-2 and
iNOS Expression
Microscopic examination for COX-2 staining as shown in Figure 3A
indicated a lower immunoreactivity in GSE-treated group. The quan-
tification of immunostaining showed that GSE significantly decreased
the expression of COX-2 in small intestine (proximal, middle, and dis-
tal portions) by 56% to 64% (P < .001) compared with the control
group (Figure 3B). In association with the down-regulation of COX-2,
the expression of iNOS in the small intestine was also inhibited by
58% to 60% (P < .001) in theGSE-fed group compared with the control
group (Figure 3, C and D). These results suggest the down-regulation
ofCOX-2 and iNOSbyGSE in small intestine of APCmin/+mice, which,
in turn, could exert anti-inflammatory and antiproliferative effects to
inhibit growth and development of polyps.
Effect of Dietary GSE on Intestinal β-Catenin and
Cip1/p21 Expression
In further studies, we examined the expression levels of β-catenin and
Cip1/p21 in different portions (proximal, middle, and distal) of the
small intestinal tissues from control and GSE-treated groups of mice
by immunostaining. A representative picture of β-catenin immuno-
staining from each group is shown in Figure 4A. The diffused staining
for β-catenin was quantified on the basis of the intensity of immuno-
reactivity. Dietary administration of 0.5% GSE for 6 weeks showed de-
creased positivity for β-catenin (43%-59%, P < .001; Figure 4B).
Further, an increased immunoreactivity for cyclin-dependent kinase in-
hibitor Cip1/p21 in the small intestine was observed by GSE treatment
compared with the control group (data not shown). The quantification
of Cip1/p21–positive cells showed a 1.9- to 2.6-fold (P < .001) increase
in GSE-treated group compared with the control group (Figure 4C ).
These observations indicated the likely inhibitory effect of GSE on
β-catenin signaling and inhibition of cell cycle regulation through an
increase in Cip1/p21 levels.
Effect of Dietary GSE on Intestinal Cyclin D1 and
c-Myc Expression
To further confirm the effect of GSE on β-catenin pathway and its
subsequent potential role in inhibition of cell cycle progression and
cell proliferation, we examined the expression levels of β-catenin sig-
naling targets, cyclin D1, and c-Myc that mediate cell cycle progres-
sion and cell proliferation (Figure 5). Intestinal sections were
immunohistochemically analyzed for cyclin D1 and c-Myc using spe-
cific antibodies (staining data not shown). The quantification of the
staining showed that dietary administration of 0.5% GSE for 6 weeks
significantly decreased the number of cyclin D1-positive cells (39%-
49%, P < .001) as well as c-Myc immunoreactivity (52%-58%, P <
.001) in the small intestine (proximal, middle, and distal portions)
compared with the control group. These results further support the
effect of GSE on β-catenin signaling and its association with the inhi-
bition of cell proliferation during polyp growth in the intestine.
Discussion
APCmin/+ mice are heterozygous for a truncating mutation in the
APC tumor-suppressor gene and provide a model of FAP and sporadic
colorectal cancers [21]. Designated as a gatekeeper in colorectal tumor-
igenesis, mutation of APC leading to the deregulation of theWnt signal
transduction pathway is one of the earliest events in colorectal neoplasia
[22,23]. Normally, in the absence of Wnt stimulation, β-catenin is tar-
geted for degradation by a cytoplasmic complex containing APC, axin,
and glycogen synthase kinase 3β. Therefore, mutation of APC gene
increases cytoplasmic accumulation and nuclear translocation of
β-catenin [24]. In the nucleus, the transcription factor, T-cell factor/
lymphoid enhancer factor, are transactivated by β-catenin leading to
Figure 2. Modulatory effects of dietary GSE on cell proliferation
and apoptosis in intestinal epithelium of APCmin/+ mouse. The
percent of (A) PCNA-positive cells and (B) TUNEL-positive cells
assessed by quantification of immunohistochemically stained
mouse intestinal epithelium in 10 randomly selected fields from
each tissue sample are represented. Data are shown as mean ± SE
of eight samples in each group.
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an increased expression of genes that regulate cell proliferation and
apoptosis [25,26]. Hence, the APCmin/+ mouse model is unique in
which tumors appear spontaneously in the gastrointestinal tract,
rather than induction by a carcinogen. Therefore, this model is par-
ticularly advantageous for testing chemopreventive agents targeted
against early-stage lesions and relevant to the design of human chemo-
prevention clinical trials because an adequate number of adenomas
grow to a grossly detectable size within a few months [19]. The concept
of dietary chemoprevention is usually applied in the context of protect-
ing normal cells from initiating events that introduce oncogenic muta-
tions. It is a well-known fact that carcinogenesis represents a progression
of cellular changes, and agents that disrupt this progression at any point
can be considered chemopreventive [27,28]. In recent years, cancer pre-
vention by dietary phytochemicals has received considerable attention.
The present study, using APCmin/+ mice, for the first time demon-
strated that dietary administration of 0.5% GSE suppressed intestinal
tumorigenesis, especially the large tumors and tumors in middle and
distal portions of the small intestine. Further, the decrease in tumor
number and size by GSE was accompanied by antiproliferative and
proapoptotic effects together with down-regulation of iNOS, COX-2
and β-catenin, cyclin D1, and c-Myc levels and by an increase in
Cip1/p21 protein level. These molecular changes suggest that the in-
hibition of β-catenin signaling could be one of the possible underly-
ing mechanisms of antitumorigenic activity of GSE. The protective
effect of GSE against intestinal tumorigenesis through inhibition of
cell proliferation and induction of apoptosis correlates with the earlier
reports on other naturally occurring dietary phytochemicals against
tumor formation in APCmin/+ mouse model [29,30].
Many cancer susceptibility genes produce defects in the regulation
of cell proliferation, differentiation, or apoptosis. It is well known
that disruption of the balance between cell proliferation and cell
death is the most important biological impetus leading to neoplasia
[31]. One approach to cancer prevention and treatment could be to
bypass these defects through alternate mechanisms or by modifying
the defective mechanisms using naturally occurring or synthetic com-
pounds. The proposed mechanisms of chemopreventive effects of GSE
in the present study include the inhibition of the intestinal tumorigen-
esis by reduction in cell proliferation and enhancement of apoptosis.
Figure 3. Effects of dietary GSE on COX-2 and iNOS expression levels in intestinal tissues of APCmin/+ mice. Representative photo-
graphs for immunohistochemical staining of (A) COX-2 and (C) iNOS-stained cells in APCmin/+ mouse control and GSE-treated groups,
respectively, are shown at 400× magnifications. (B) COX-2 and (D) iNOS expression levels were assessed by the quantification of the
specific immunostaining of mouse intestinal epithelium in 10 randomly selected fields as described in Materials and Methods. Data are
shown as mean ± SE of eight samples in each group.
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Colon cancer development is often characterized in an early stage
by a hyperproliferation of the epithelium leading to the formation of
adenomas. In this multistep process, an early intervention should
inhibit enhanced cell proliferation of transformed cells and, more im-
portantly, the induction of the apoptotic pathway to delete the cells
carrying mutations. Inhibition of apoptosis is a major mechanism in
colon carcinogenesis and contributes to the development of colon
tumor from the premalignant colonic epithelial cells [32]. Thus,
identifying the mechanisms and approaches that upregulate the apop-
totic processes will provide useful strategies for regulating colon tumor
growth. Apoptosis is now considered to be an important target in iden-
tifying chemopreventive agents against colon cancer. This has been
supported by several chemopreventive agents that have been shown
to inhibit colon tumor growth by enhancing apoptosis [33]. The in-
crease in intestinal epithelial cell apoptosis in the present study
strengthens our belief that GSE-induced apoptosis could be important
in controlling intestinal tumorigenesis. Our previous study in the cell
culture showed that GSE increases cleaved levels of caspase-3 and poly
(ADP-ribose) polymerase in human CRC cells [34]. However, further
studies are needed to explore the GSE-induced intestinal cell apoptosis
in APCmin/+ mice.
Preclinical and clinical studies suggest that COX-2 is involved in
chronic inflammation and plays a crucial role in colon adenoma devel-
opment [35]. Mutations of the APC gene have been notably linked
Figure 4. Effect of dietary GSE on β-catenin and Cip1/p21 expres-
sion levels in intestinal tissue of APCmin/+ mice. Representative
photographs for immunohistochemical staining of β-catenin posi-
tivity (A) in APCmin/+ mouse control and GSE-treated groups are
shown at 400× magnifications. (B) Immunopositivity of β-catenin
and (C) Cip1/p21–positive cells were assessed by quantification
of immunohistochemically stained mouse intestinal epithelium in
10 randomly selected fields as described in Materials and Methods.
Data are shown as mean ± SE of eight samples in each group.
Figure 5. Effect of dietary GSE cyclin D1 and c-Myc expression
levels in intestinal tissue of APCmin/+ mice. (A) Cyclin D1–positive
cells and (B) immunopositivity of c-Myc were assessed by quanti-
fication of immunohistochemically stained mouse intestinal epi-
thelium in 10 randomly selected fields as described in Materials
and Methods. Data are shown as mean ± SE of eight samples
in each group.
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with the overexpression of the COX-2 gene in a majority of colon
cancers [36]. COX enzymes play a central role in the conversion of ara-
chidonic acid to prostaglandins. One of the COX-2 reaction products,
prostaglandin E2, is known to lead to the induction of cell proliferation
and the inhibition of apoptosis that favor tumor development [37]. In
colon carcinogenesis, overexpression of COX-2 has been observed in
aberrant crypt foci, adenomas, and adenocarcinomas, suggesting its
contribution to the growth of precursor lesions and tumors and their
further progression [38]. Thus, suppression of COX activity is suggested
to be one of the potential mechanisms for inhibition of carcinogenesis.
Recent reports suggest that in addition to COX-2, iNOS may contrib-
ute to tumor development or acceleration of the early stage of tumori-
genesis [39]. The elevated expression of iNOS has also been reported
in carcinogen-induced rat colon cancers [40]. Moreover, elevated levels
of iNOS have been detected in most adenomas and dysplastic lesions,
suggesting that iNOS plays an important role in colon carcinogenesis
[40]. In the current study, dietary administration of GSE reduced in-
testinal COX-2 and iNOS levels, and this may account for lowering the
number of intestinal adenomas. Because inhibition of COX-2 and
iNOS expression results in decreased cell proliferation and increased
apoptosis [41], the reduction of COX-2 and iNOS expressions in the
present studymight contribute to the modulatory effects of GSE on cell
proliferation and apoptosis.
Mutations in APC or β-catenin reported in many of human and
experimental colon tumors either repress the degradation of β-catenin
or accumulate cellular β-catenin that leads to the activation of oncogenic
pathways [42]. β-Catenin signaling induces colonic hyperproliferation
through the regulation of its target molecules, including Cip1/p21,
cyclin D1, and c-Myc [42,43]. Active β-catenin/wnt signaling decreases
Cip1/p21 level but increases cyclinD1 level, preventing cells from enter-
ing G1 arrest or differentiation, thereby allowing cells to proliferate [44].
In addition to interactions with cyclin-CDK complexes, Cip1/p21 has
also been reported to inhibit cell cycle progression through the inter-
action with PCNA [45]. PCNA has been found in Cip1/p21–cyclin–
CDK complexes and Cip1/p21 blocks the ability of PCNA to activate
DNA polymerase delta, the principal replicative DNA polymerase [46].
Further, the disruption of Cip1/p21 expression leads to decreased cell
death, suggesting its role in proapoptotic function [47,48]. In a recent
study, apoptosis of colonic epithelial cells was reduced in mice deficient
for Cip1/p21 after treatment with the colon carcinogen azoxymethane
[49]. Conditional inactivation of c-Myc in APCmin/+ mice is found to
suppress APC-dependent intestinal tumorigenesis along with an in-
crease in apoptosis [50]. These studies suggest that GSE-mediated de-
crease in β-catenin together with an increase in Cip1/p21 and a decrease
in cyclin D1 and c-Myc levels in the present study could contribute to
both apoptosis and antiproliferative effects during inhibition of intesti-
nal tumorigenesis. A recent report from our laboratory also suggests that
GSE inhibits in vitro and in vivo growth of human colorectal carcinoma
cells through an up-regulation of Cip1/p21 [34].
In summary, the present investigation has provided the first evi-
dence for inhibition of intestinal tumorigenesis by dietary feeding
of GSE in APCmin/+ mouse model. The suppression of proliferation
and stimulation of apoptosis could involve the down-regulation of
COX-2, iNOS, and β-catenin, cyclin D1 and c-Myc expression,
and an up-regulation of Cip1/p21 as possible mechanisms by which
GSE inhibits intestinal tumorigenesis in this animal model. These
findings together with our earlier studies suggest that chemopreven-
tion using dietary GSE could be a promising approach for colon cancer
prevention in high-risk individuals, such as FAP carriers.
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